Effects of treatment intensification with hydroxyurea in HIV-infected patients with virologic suppression

AIDS

Volumn 15, Issue 11, 2001, Pages 1379-1388

  Havlir, Diane V ^a   Gilbert, Peter B ^b   Bennett, Kara ^b   Collier, Ann C ^d   Hirsch, Martin S ^c   Tebas, Pablo ^e   Adams, Elizabeth M ^f   Wheat, L Joseph ^g   Goodwin, Diane ^h   Schnittman, Steven ⁱ   Holohan, M K ^f   Richman, Douglas D ^j  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c HARVARD UNIVERSITY   (United States)

^d UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^e WASHINGTON UNIVERSITY   (United States)

^f AIDS Clinical Trials Group Operations Center   (United States)

^g INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h GLAXOSMITHKLINE   (United States)

ⁱ BRISTOL MYERS SQUIBB   (United States)

^j University of California San Diego ^*

more..

Author keywords

Didanosine; Drug toxicity; Hydroxyurea; Indinavir; Stavudine; Therapy intensification

Indexed keywords

DIDANOSINE; HYDROXYUREA; INDINAVIR; LAMIVUDINE PLUS ZIDOVUDINE; STAVUDINE; VIRUS RNA;

ADULT; ANEMIA; ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG POTENCY; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER TOXICITY; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; PANCREATITIS; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA; TREATMENT FAILURE; VOMITING;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; CASE-CONTROL STUDIES; CD4 LYMPHOCYTE COUNT; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; FEMALE; HIV INFECTIONS; HUMANS; HYDROXYUREA; INDINAVIR; LAMIVUDINE; MALE; NUCLEIC ACID SYNTHESIS INHIBITORS; PANCREATITIS; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT FAILURE; VIRAL LOAD; ZIDOVUDINE;

EID: 0035958764     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200107270-00007     Document Type: Article

References (33)

1. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy
2. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults
3. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection
4. Effect of chemokine receptor gene polymorphisms on the response to potent antiretroviral therapy
5. Maintenance antiretroviral therapies in HIV infected patients with undetectable plasma HIV RNA after triple-drug therapy
6. A randomized trial of three maintenance regimens given after three months of induction therapy with zidovudine, lamivudine, and indinavir in previously untreated HIV-1-infected patients
7. Maintenance therapy after quadruple induction therapy in HIV-1 infected individuals: Amsterdam Duration of Antiretroviral Medication (ADAM) study
8. Hydroxyurea as an inhibitor of human immunodeficiency virus-type 1 replication
9. A pilot study of hydroxyurea among patients with advanced human immunodeficiency virus (HIV) disease receiving chronic didanosine therapy: Canadian HIV trials network protocol 080
10. Anti-HIV activity of the combination of didanosine and hydroxyurea in HIV-1-infected individuals
11. A placebo-controlled trial of didanosine plus stavudine, with and without hydroxyurea, for HIV infection
12. Hydroxyurea and didanosine is a more potent combination than hydroxyurea and zidovudine
13. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents
14. Antiretroviral therapy in adults - Updated recommendations of the International AIDS Society-USA Panel
15. HIV population dynamics in vivo: Implications for genetic variation, pathogenesis, and therapy
16. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection
17. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma
18. An overview of the clinical experience with hydroxyurea
19. A randomized study of the safety and antiretroviral activity of hydroxyurea combined with didanosine in persons infected with human immunodeficiency virus type 1
20. Treatment of human immunodeficiency virus infection with hydroxyurea: Virologic and clinical evaluation
21. Pancreatitis incidence rates of patients treated in 20 adult antiretroviral treatment trials
22. Acute pancreatitis in human immunodeficiency virus-infected patients: A review
23. Acute necrotizing pancreatitis
24. Lactic acidosis and hepatic steatosis associated with use of stavudine: Report of four cases
25. Incidence of neuropathy in HIV-infected patients on monotherapy versus those on combination therapy with didanosine, stavudine and hydroxyurea
26. Hydroxyurea-induced hepatitis in human immunodeficiency virus-positive patients
27. Hyperlactatemia and hepatic abnormalities in 10 human immunodeficiency virus-infected patients receiving nucleoside analogue combination regimens
28. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection
29. The effects of hydroxyurea or placebo combined with efavirenz, didanosine, and stavudine in treatment naive and experienced patients: Preliminary 24 week results from the 3d study